MedTrace Logo

Gastrin-Releasing Peptide and Bronchopulmonary Dysplasia

NCT01748565 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 260

Last updated 2024-04-12

No results posted yet for this study

Summary

The purpose of this study is to identify biological markers that might predict premature infants who are at a higher risk for developing BPD, and to correlate the presence of these markers with infant symptoms and lung function in the first year after discharge from the hospital.

Conditions

  • Bronchopulmonary Dysplasia
  • Prematurity

Sponsors & Collaborators

  • Indiana University

    collaborator OTHER

  • University of North Carolina, Chapel Hill

    collaborator OTHER

  • Duke University

    lead OTHER

Principal Investigators

  • Charles M Cotten, MD · Duke University

Eligibility

Max Age
7 Days
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2016-08-31
Completion
2016-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01748565 on ClinicalTrials.gov